Goldman initiated coverage of ResMed with a rating of Buy
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/16/2025 | Buy | Goldman | |
| 1/10/2025 | $252.00 | Neutral | Piper Sandler |
| 12/13/2024 | $250.00 | Hold | Stifel |
| 9/24/2024 | $280.00 | Outperform | Robert W. Baird |
| 9/18/2024 | $180.00 | Peer Perform → Underperform | Wolfe Research |
| 9/4/2024 | Buy → Hold | Needham | |
| 6/25/2024 | Outperform → Perform | Oppenheimer | |
| 6/24/2024 | Buy → Neutral | Citigroup |
SAN DIEGO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- ResMed (NYSE:RMD, ASX: RMD)) today announced it plans to release financial and operational results for the second quarter of fiscal year 2025 on Thursday, January 30, 2025, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: • Location:https://investor.resmed.com• Date:Thursday, January 30, 2025• Time:1:30 p.m. PST / 4:30 p.m. EST• International:London, Thursday, January 30, 2025, 9:30 p.m. GMT Sydney, Friday, January 31, 2025, 8:30 a.m. AEDT Please no
SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- ResMed (NYSE:RMD, ASX: RMD)) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, beginning at approximately 3:00 p.m. (Pacific Standard Time) in San Francisco, CA. More information about this event, including access to the live, audio-only webcast, may be accessed by visiting https://investor.resmed.com. The audio-only webcast replay will be available approximately 24 hours after the live webcast ends and will be accessible for the following thirty (30) days. About ResMedAt ResMed (NYSE:RMD
Issued on behalf of Avant Technologies Inc. USA News Group News Commentary VANCOUVER, BC, Nov. 12, 2024 /PRNewswire/ -- Recently the World Economic Forum released a report that highlights AI's potential to relieve pressure on healthcare systems worldwide, with Mayo Clinic's early adoption showing how AI can drive progress. Elon Musk has also hinted that his company's Grok AI could have applications in medical image analysis. At this year's HLTH conference in Las Vegas, tech giants like Nvidia, Google, and Microsoft presented their latest AI healthcare tools. Meanwhile, a range of emerging tech companies are making strides in AI-powered healthcare, including: Avant Technologies, Inc. (OTCQB:
SC 13G/A - RESMED INC (0000943819) (Subject)
SC 13G/A - RESMED INC (0000943819) (Subject)
SC 13G/A - RESMED INC (0000943819) (Subject)
8-K - RESMED INC (0000943819) (Filer)
DEFA14A - RESMED INC (0000943819) (Filer)
10-Q - RESMED INC (0000943819) (Filer)
4 - RESMED INC (0000943819) (Issuer)
4 - RESMED INC (0000943819) (Issuer)
4 - RESMED INC (0000943819) (Issuer)
SAN DIEGO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- ResMed (NYSE:RMD, ASX: RMD)) today announced it plans to release financial and operational results for the second quarter of fiscal year 2025 on Thursday, January 30, 2025, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: • Location:https://investor.resmed.com• Date:Thursday, January 30, 2025• Time:1:30 p.m. PST / 4:30 p.m. EST• International:London, Thursday, January 30, 2025, 9:30 p.m. GMT Sydney, Friday, January 31, 2025, 8:30 a.m. AEDT Please no
Year-over-year revenue grows 11%, operating profit up 34%, non-GAAP operating profit up 27%Operating cash flow of $326 million Note: A webcast of ResMed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, Oct. 24, 2024 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE:RMD, ASX: RMD))) today announced results for its quarter ended September 30, 2024. First Quarter 2025 HighlightsAll comparisons are to the prior year period Revenue increased by 11% to $1.2 billion; up 11% on a constant currency basis Gross margin improved 420 bps to 58.6%; non-GAAP gross margin improved 320 bps to 59.2%Income from operations increased 34%; non-GAAP income from operation
SAN DIEGO, Oct. 03, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE:RMD, ASX: RMD))) today announced it plans to release financial and operational results for the first quarter of fiscal year 2025 on Thursday, October 24, 2024, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Location: http://investor.resmed.com Date: Thursday, October 24, 2024 Time: 1:30 p.m. PDT / 4:30 p.m. EDT International: London, Thursday, October 24, 2024, 9:30 p.m. BSTSydney, Friday, October 25, 2024, 7:30 a.m.
Goldman initiated coverage of ResMed with a rating of Buy
Piper Sandler initiated coverage of ResMed with a rating of Neutral and set a new price target of $252.00
Stifel initiated coverage of ResMed with a rating of Hold and set a new price target of $250.00
DelOrefice is the Chief Financial Officer at BD, one of the largest global MedTech companies in the worldBoard appointment brings over 30 years of strategic and operational finance expertise SAN DIEGO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE:RMD, ASX: RMD))) today announced it has expanded the size of its board of directors to 11 and has elected Christopher DelOrefice to the board, effective immediately. Mr. DelOrefice was appointed during ResMed's regularly scheduled board meeting on August 15, 2024, and will stand for re-election with the rest of ResMed's directors at its annual meeting on November 21, 2024. Mr. DelOrefice has also been appointed as a member of ResMed's board au
Rider and Haake, both internal promotions, joined ResMed's executive team on May 1Rider, currently Senior Vice President, Deputy Global General Counsel will succeed retiring Chief Administrative Officer, Global General Counsel, and Secretary David Pendarvis on July 1 SAN DIEGO, May 02, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE:RMD, ASX: RMD))) today announced the appointment of two new executive team members: Michael Rider, Global General Counsel & Secretary, effective July 1, 2023, and Dawn Haake as ResMed's first Chief Quality Officer, effective May 1, 2023. Both joined ResMed's executive team on May 1 and report to the Office of the CEO. Michael Rider was selected following a previously a
SAN DIEGO, Jan. 26, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE:RMD, ASX: RMD))) today announced ResMed's board of directors has appointed chief executive officer Michael ("Mick") Farrell as chair of the board, effective January 25, 2023. Mr. Farrell succeeds current chair Peter Farrell who will become chair emeritus and will remain an active board member. Mick Farrell became ResMed's CEO on March 1, 2013, and has served as a member of the company's board of directors since assuming that role. "I am honored to expand my role with ResMed as its next chair and to succeed my dad, Peter Farrell, whose vision, leadership, and guidance have helped ResMed become the largest outside-hospital, digital